Author

Qinlei Huang

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5137115809

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

2026 · Matthew D. Galsky, Begoña P. Valderrama, et al. · New England Journal of Medicine · 22

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.

2026 · Christopher J. Hoimes, Matthew D. Galsky, et al. · Journal of Clinical Oncology

Works count: 2

Citation count: 22

H-index: 1

I10-index: 1